The first drug receptor assay was described in 1966 by Lowenstein and Corrill' but progress in the field has been fairly slow since then ( Table 1) . One of the reasons for this is perhaps a poor understanding of the advantages offered by receptor assays over current monoclonal specific immunoassays. Theoretically, a receptor assay offers advantages whenever there is a situation in which a drug (pharmacologically active or inactive) is converted into metabolites which have varying degrees of pharmacologic activity. Examples of this type of situation include digoxin and cyclosporine. In these instances, a specific monoclonal antibody which reacts only with the parent drug will not quantify the pharmacologically active metabolites. A polyclonal antibody may cross-react with both pharmacologically active and inactive metabolites and the degree or extent of crossreactivity is unlikely to be related to pharmacological activity. For example, the aglycone metabolite of digoxin, digoxigenin, has little to no drug activity but cross-reacts significantly (on a weight-for-weight basis greater than digoxin) in most digoxin imrmmoassavs.' Indeed, one of the potential advantages of receptor assays over immunoassays is that the cross-reactivity of metabolites in receptor assays may well parallel their pharmacological activity so that receptor assays may well provide an 'activity' index. This would appear to be the case for the digoxin metabolites.'
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DIGOXIN RECEPTOR ASSAYS
This work was followed by a report by Burnett and Conklin;' who extracted digoxin and its metabolites from 3 mL of heparinized plasma with a 95/5 (v/v) mixture of methylene chloride/ n-amyl alcohol. After evaporation of the organic not followed up with clinical studies evaluating its use. More recently, Soldin et alY described a radioreceptor assay for glucocorticoids using the partially purified human liver glucocorticoid receptor. Prednisone, prednisolone and methylprednisolone are among the 10 most commonly prescribed drugs and are used in over 10% of hospitalized patients. IS Many of these patients develop one or more clinical signs of drug toxicity such as features of Cushing's syndrome. Therapeutic drug monitoring has played almost no role in optimizing the drug treatment of these patients.
Reasons for this include difficulties in the interpretation of plasma drug concentrations due to the 'first-pass' effect, involving the metabolism of inactive prednisone to active prednisolone and reconversion. Other factors which complicate interpretation are the increases in volume of distribution, metabolic clearance and renal clearance of prednisolone with dose. These effects appear to be due to saturable binding of prednisolone to transcortin in plasma, providing more unbound drug at high plasma concentrations. 19
In a recent study, Lipnick et 01. 20 have found that a good correlation exists between the degree of Cushingoid features and the peak concentration or area under the serum concentration (measured in prednisolone equivalents) versus time curve using the radioreceptor assay of Soldin et 01. 17 in patients with juvenile rheumatic diseases (Figs I and 2). The correlation between free or total cortisol area under the curve and degree of Cushingoid features was poor. Clearly, the specificity of the receptor assay is such that it provides important clinical information which cannot be gleaned from simple immunoassays for cortisol. 20 This is an exciting new development which may mean that the management of patients The glucocorticoid receptor has been well studied, sequenced and cloned, and a glucocorticoid receptor assay was first proposed by Ballard et 01. 16 in 1975. These researchers used the crude cytosol obtained from rat hepatoma cells as the source of glucocorticoid receptor in their assay, but their initial studies describing the assay were THE GLUCOCORTICOID RECEPTOR ASSAY phase, the dried extract was tested for its ability to inhibit hog-brain ATP-ase. Both of the above methods required large sample volumes and were impractical for routine clinical use, especially in a paediatric setting. These assays were soon replaced by a multitude of digoxin immunoassays which had the advantage of requiring smaller sample volumes and were generally simpler to perform with a fairly short (approximately 4 h) turnaround time.v '? Digoxin has been routinely measured in the clinical laboratory by immunoassay for the past two and a half decades. Even though these immunoassays have improved with time, there is still a rather poor correlation between apparent serum concentration and efficacy or toxicity.!' This is undoubtedly due to a combination of factors which include lack of specificity of digoxin immunoassays with cross-reactivity to digoxinlike factors." Of even greater concern is the more recent evidence that digoxin is fairly extensively metabolized in of the population and that digoxin immunoassays crossreact with many of the metabolites in a manner which does not correlate to their pharmacologic activity.13,14 Dissatisfaction with current immunoassays for digoxin led to a re-examination of digoxin receptor assays using dog kidney and human heart ATP-ases. 2, 15 The specificity of the receptor assay using human heart ATP-ase was significantly better than current immunoassays with minimal interference by digoxin-like factors found in the third trimester of pregnancy, in patients with liver and renal disease and in neonates.P Nevertheless, the receptor assay is tedious, requires a human heart ATP-ase preparation and is clearly unsuitable for routine use in a busy clinical laboratory. One of the major current drawbacks of this approach is that the receptor is membrane-bound, which severely limits its marketability. A soluble or cloned receptor and its use in the digoxin receptor assay may be the direction in which this work should now proceed. The specific monoclonals measure largely parent drug and so do not measure pharmacologic activity due to active metabolites. The nonspecific polyclonal antibody procedures on the other hand cross-react with metabolites which are pharmacologically active or inactive. The degree of crossreactivity does not, however, correlate with pharmacological activity.
Recently, our research has focused on immunosuppressive drug receptors and, in particular, binding proteins to CsA, FK-506 and rapamycin. These binding proteins have been isolated and purified from the Jurkat T-helper cell line" and from calf thymus and human spleen. Table 2 lists the proteins isolated and the drugs which bind to each of them. Note that cyclophilin (previously characterized by Handschurnacher)" and FKbinding protein (FKBP, previously characterized by Sierkierka et a/.)34 are ubiquitous proteins present in fairly high concentrations in mammalian tissues. Cyclophilin binds only CsA and FKBP binds only FK-506 and rapamycin. In contrast the quantitatively minor binding proteins of 50-58 KDa and approximately 100 KDa bind all three immunosuppressive drugs with great avidity (see dissociation constants in Table 3 ) and have been found to be present in T-helper cells, spleen and thymus but could not be isolated in our laboratory from liver and kidney tissue. Rapamycin can displace FK-506 from the 50-58 KDa protein but does not displace CsA. FK-506 can displace both CsA and rapamycin from their binding sites on the protein."
The 50-58 KDa and 100 KDa proteins are far more likely to be the true receptors to CsA, FK-506 and rapamycin than are cyclophilin and FKBP. The dissociation constants and the low concentrations at which these minor immunophilins are present also suggests that in contrast to cyclophilin and FKBP. these proteins would 
Binding proteins to immunosuppressive drugs
The radioligand dopamine receptor binding displacement assay is available commercially in kit form and enables the examination of dopamine receptor displacement activity in serum samples obtained from patients treated with neuroleptic drugS. 21 ,22 The assay measures the quantity of neuroleptic and metabolites that displace a radiolabelled ligand from dopamine receptors obtained from homogenates of the caudate nucleus. The advantages of this technique include high sensitivity, low cost and the theoretical ability to measure antidopaminergic activity of the parent drug and all active metabolites. Serum concentrations of responders and non-responders for haloperidol and chlorpromazine are virtually identical using conventional tecbniques.P-" The on steroids could be optimized through therapeutic drug monitoring by measuring their serum concentration versus time profile on onset of therapy and then adjusting the steroid dose to minimize toxic side effects. These preliminary studies clearly need to be expanded to study other groups of patients receiving glucocorticoid treatment. 
Dissociation constants of immunosuppressant drugs for their binding proteins
become saturated or near saturated with drug at the concentrations at which these drugs have been found to be pharmacologically effective.
A radioreceptor assay for the measurement of cyclosporine activity was first reported by Donnelly and Soldin in 1989. 36 This assay employed cyclophilin as a binding protein. A second receptor assay for CsA employing the 50-58 KDa protein was also developed in our laboratories. Both receptor assays, and the specific and nonspecific immunoassays, were assessed against a mixed lymphocyte culture (MLC) assay to determine which of these techniques provided data which correlated best with immunosuppression." Table 4 summarizes the results obtained. By far the best correlation with immunosuppression was obtained with the 50 KDa receptor assay. Interestingly, in this preliminary study, a better correlation was found for the nonspecific fluorescent polarization immunoassay (FPIA) procedure than with the specific monoclonal FPIA method. Our laboratory is currently trying to assess these different receptor assays in specific transplant groups and we hope to have data to report in the near future. Finally, we have also recently developed receptor (protein-binding) assays for FK-506 and rapamycin which utilize either FKBP or the 50 KDa protein as the receptors (manuscripts in preparation). Again, these receptor proteins need to be cloned and receptor assays evaluated in large studies of specific (e.g. heart, liver, kidney or bone marrow) transplant groups. Much more work needs to be done to demonstrate whether or not this approach has significant advantages over conventional immunoassays. •A test of the equality of the regression lines and slopes was used to determine if the differences in correlation coefficients were significant between the two RRAs and the two TDx assays. The test of equality is as follows: Residual SS within groups = I: gm up , residual SS of the group The slopes and regression lines of both RRAs differed significantly from the two TDx assays. tAbbott Laboratories, North Chicago, IL, USA. RRA= Radioreceptor assay.
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